Onco Actu du 10 avril 2017

	3.3 Prévention - Vaccins
Short Answers to Hard Questions About HPV [NY Times] Recent data from a survey by the Centers for Disease Control and Prevention found that in the decade since the vaccine was introduced, cases of HPV infection in teenage girls had decreased by almost two-thirds.
	4. Dépistage, diagnostic et pronostic
Advancing the Potential and Promise of Total-Body PET Imaging [NCI] This new PET scanner, whose development has received substantial financial support from NCI and NIBIB, is designed to rapidly provide detailed information about tissues throughout the entire body while using a much smaller amount of radioactivity than a standard PET scan.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA Offers its Views on Medical Device Trials [RAPS] Unlike for pharmaceuticals, which generally see double-blind, randomized, Phase 3 trials assessing outcomes prior to approval, "practical limitations related to the device or disease condition require alternative approaches" for many devices, CDRH’s Owen Faris and Jeffrey Shuren write.
	4.11 Dép., diag. & prono. - Ovaire
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene's Novel PARP Inhibitor, BGB-290 [Myriad] Under the agreement, BeiGene will use Myriad's myChoice® HRD and BRACAnalysis CDx® companion diagnostic tests to support the clinical development of its novel PARP inhibitor, BGB-290.
PET imaging measures PARP-1 in ovarian cancer patients [FierceBiotech] Aside from identifying patients who might benefit from PARP-1 drugs, the new tracer and imaging method could be used to check whether the treatment is working, Makvandi said.
	5. Traitements
Sperm Loaded with Drugs Could Target Gynecological Cancers [MIT Technology Review] The system is simple in essence. Medina-Sánchez and co simply soak sperm in the active ingredient, which causes the sperm cells to take up surprisingly large doses. They then force the sperm to swim into a kind of mechanical harness—a self-tightening micromachined structure that attaches to the head of the sperm.
	5.12 Immunothérapies
Trial Of Immune Drug In Breast Cancer Points To Need For Biomarkers [Forbes] What struck me about this trial of atezolizumab is that a few breast cancer patients really do benefit. The problem is, there’s no way to know in advance who those patients will be.
	5.12.3 Immunothérapies-combinaisons
Immuno-oncology (IO) combination therapy- why the angst? [SugarCone Biotech] Why the perception of angst then? The sentiment has been summed up as “everything will work a little, so what do we research/fund/advance? How do we choose? How will we differentiate”?
Angst in the IO Combo field – part 2 (lessons from #AACR17) [SugarCone Biotech] At AACR, Dan Chen (from Genentech, a Roche company) laid out the case for using not 1, not 2, not 3, not 4, not 5 … but up to 11 different therapeutics to successfully treat a given tumor – he exaggerated to make the point that none of the current immune checkpoint inhibitors (ICIs) should be expected to work in synergy with anti-PD-1 therapy, a priori.
	5.2 Pharma
Jazz Pharmaceuticals submits FDA application for leukaemia treatment [European Pharmaceutical Review] Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos (cytarabine and daunorubicin) liposome for injection, an investigational treatment for acute myeloid leukemia.
Medivir posts lymphoma data, guns to get into phase 3 [FierceBiotech] Investigators enrolled 60 patients with the slow-growing mycosis fungoides form of CTCL, a type of non-Hodgkin lymphoma that initially manifests as eczemalike skin patches. Medivir randomized the participants to receive one of three regimens of topical HDAC inhibitor remetinostat.
Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer [Roche] Full data from the ALEX study will be presented at an upcoming medical meeting and submitted to global health authorities.
	5.3 Traitements - FDA, EMA, NICE...
Scott Gottlieb’s FDA Commissioner Confirmation Hearing: Remarkably Unremarkable [Health Affairs Blog] Dr. Gottlieb was asked about four categories of issues that are worth considering for insight into how is he is likely to lead the agency. Further, he was not asked about a fifth issue that in my view is critically important for the next commissioner.
Congress and FDA nominee heap love on ‘adaptive trials’ [Science] A recent survey of researchers’ attitudes toward adaptive trials found that biostatisticians were also generally less optimistic than other stakeholders about the validity of conclusions from adaptive trials.
FDA unease about faster drug approval [BMJ] The report is a surprisingly thorough compilation of 22 specific case studies of drugs, vaccines, and medical devices. In each case, the product showed promising results in phase II studies but failed to shine in phase III trials—and ultimately was not approved for the intended indication
	5.9 AACR
Delivering Cures Through Cancer Science - 2016 Annual Report [AACR] By any measure, 2016 was a spectacular year for the AACR.
Speaking of Cancer Research [The Scientist] Notable quotes from this year’s annual meeting of the American Association for Cancer Research.
	6.1 Observation
Lots of sleep tied to worse breast cancer survival odds [Reuters] For the study, researchers examined data on post-diagnosis sleep duration for 3,682 women with breast cancer. They also examined pre-diagnosis sleep duration in a subset of 1,949 women and post-diagnosis sleep difficulties in a subset of 1,353 women.
More prostate cancer patients get radiation when doctors own the equipment [Reuters] Compared with men diagnosed by specialists who didn't own radiation machines, men diagnosed by urologists who did own equipment were 61 percent more likely to receive surgery or radiation, researchers report in the journal Prostate Cancer and Prostatic Diseases.
	6.10.1 Politiques (USA)
Biden: Trump’s cuts would set back cancer research by 15 years [The Cancer Letter] At a panel discussion that followed Biden’s speech, Rep. Kevin Yoder (R-KS) said Republican members of Congress will not renege on their support for NIH and biomedical research.
	6.9 Controverses
How Washington’s favorite cancer fighter helps himself [Politico] Patrick Soon-Shiong is a philanthropist and a businessman. But a prime target of his philanthropy is his businesses.